Antiangiogenic gene therapy for hepatocellular carcinoma using angiostatin gene

Hepatology

Volumn 37, Issue 3, 2003, Pages 696-704

  Ishikawa, Hiroki ^a   Nakao, Kazuhiko ^b   Matsumoto, Kojiro ^a   Ichikawa, Tatsuki ^a   Hamasaki, Keisuke ^a   Nakata, Keisuke ^a   Eguchi, Katsumi ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; PIGMENT EPITHELIUM DERIVED FACTOR; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIUM CELL; EXPRESSION VECTOR; GENE DELIVERY SYSTEM; GENE THERAPY; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOLECULAR CLONING; PRIORITY JOURNAL; TREATMENT PLANNING; TUMOR VASCULARIZATION;

EID: 0037372605     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50077     Document Type: Article

References (38)

1. Yu MC, Yuan JM, Govindarajan S, Ross RK. Epidemiology of hepatocellular carcinoma. Can J Gastroenterol 2000;14:703-709.
2. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999;353: 1253-1257.
3. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002;122:1609-1619.
4. Gomez-Navarro J, Curiel DT, Douglas JT. Gene therapy for cancer. Eur J Cancer 1999;35:867-885.
5. Ruiz J, Mazzolini G, Sangro B, Qian C, Prieto J. Gene therapy of hepatocellular carcinoma. Dig Dis 2001;19:324-332.
6. Ishikawa H, Nakata K, Mawatari F, Ueki T, Tsuruta S, Ido A, Nakao K, et al. Utilization of variant-type of human alpha-fetoprotein promoter in gene therapy targeting for hepatocellular carcinoma. Gene Ther 1999;6: 465-470.
7. Ido A, Nakata K, Kato Y, Nakao K, Murata K, Fujita M, Ishii N, et al. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. Cancer Res 1995;55:3105-3109.
8. Kong HL, Crystal RG. Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst 1998;90:273-286.
9. Part YZ, Hassan MM, Lozano RD, Ellis LM, Peterson JA, Waugh KA. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol 2000;23;319-321.
10. Kin M, Torimura T, Ueno T, Nakamura T, Ogata R, Sakamoto M, Tamaki S, et al. Angiogenesis inhibitor TNP-470 suppresses the progression of experimentally-induced hepatocellular carcinoma in rats. Int J Oncol 2000;16:375-382.
11. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79: 315-328.
12. Cao Y, Ji RW, Davidson D, Schaller J, Marti D, Sohndel S, McCance SG, et al. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J Biol Chem 1996;271:2946129467.
13. Tanaka T, Cao Y, Folkman J, Fine HA. Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res 1998;58:3362-3369.
14. Leavesley DI, Schwartz MA, Rosenfeld M, Cheresh DA. Integrin beta 1- and beta 3-mediated endothelial cell migration is triggered through distinct signaling mechanisms. J Cell Biol 1993;121:163-170.
15. Yamasaki S, Kawakami A, Nakashima T, Nakamura H, Kamachi M, Honda S, Hirai Y, et al. Importance of NF-kappaB in rheumatoid synovial tissues: in situ NF-kappaB expression and in vitro study using cultured synovial cells. Ann Rheum Dis 2001;60:678-684.
16. Gao G, Li Y, Gee S, Dudley A, Fant J, Crosson C, Ma JX. Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5. J Biol Chem 2002;277:9492-9497.
17. Cianchi F, Cortesini C, Bechi P, Fantappie O, Messerini L, Vannacci A, Sardi I, et al. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001;121:1339-1347.
18. Dong Z, Kumar R, Yang X, Fidler IJ. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997;88:801-810.
19. Soff GA. Angiostatin and angiostatin-related proteins. Cancer Metastasis Rev 2000;19:97-107.
20. Ji WR, Castellino FJ, Chang Y, Deford ME, Gray H, Villarreal X, Kondri ME, et al. Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis. FASEB J 1998;12:1731-1738.
21. Chen QR, Kumar D, Stass SA, Mixson AJ. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res 1999;59:3308-3312.
22. Moser TL, Stack MS, Asplin I, Enghild JJ, Hojrup P, Everitt L, Hubchak S, et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A 1999;96:2811-2816.
23. Redlitz A, Daum G, Sage EH. Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells. J Vasc Res 1999;36:28-34.
24. Gupta N, Nodzenski E, Khodarev NN, Yu J, Khorasani L, Beckett MA, Kufe DW, et al. Angiostatin effects on endothelial cells mediated by ceramide and RhoA. EMBO Rep 2001;2:536-540.
25. Sun HC, Tang ZY, Li XM, Zhou YN, Sun BR, Ma ZC. Microvessel density of hepatocellular carcinoma: its relationship with prognosis. J Cancer Res Clin Oncol 1999;125:419-426.
26. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, Hubet J, et al. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. HEPATOLOGY 2002;35:834-842.
27. Fukumori T, Nishitani M, Naroda T, Onishi T, Oka N, Kanayama H, Kagawa S. Expression of angiostatin cDNA in a murine renal cell carcinoma suppresses tumor growth in vivo. Urology 2002;59:973-977.
28. Folkman J, Cole P, Zimmerman S. Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg 1966;164:491-502.
29. Cao Y. Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol 2001;33:357-369.
30. Barajas M, Mazzolini G, Genove G, Bilbao R, Narvaiza I, Schmitz V, Sangro B, et al. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. HEPATOLOGY 2001;33:52-61.
31. Folkman J. Antiangiogenic gene therapy. Proc Natl Acad Sci U S A 1998; 95:9064-9066.
32. Sedlacek HH. Pharmacological aspects of targeting cancer gene therapy to endothelial cells. Crit Rev Oncol Hematol 2001;37:169-215.
33. Klauber N, Rohan RM, Flynn E, D'Amato RJ. Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470. Nat Med 1997;3:443-446.
34. te Velde EA, Voest EE, van Gorp JM, Verheem A, Hagendoorn J, Gebbink MF, Borel Rinkes IH. Adverse effects of the antiangiogenic agent angiostatin on the healing of experimental colonic anastomoses. Ann Surg Oncol 2002;9:303-309.
35. Feldman AL, Libutti SK. Progress in antiangiogenic gene therapy of cancer. Cancer 2000;89:1181-1194.
36. Mauceri HJ, Seetharam S, Beckett MA, Lee JY, Gupta VK, Gately S, Stack MS, et al. Tumor production of angiostatin is enhanced after exposure to TNF-alpha. Int J Cancer 2002;97:410-415.
37. Gorski DH, Mauceri HJ, Salloum RM, Gately S, Hellman S, Beckett MA, Sukhatme VP, et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 1998;58:5686-5689.
38. Sato TN. A new approach to fighting cancer? Proc Natl Acad Sci U S A 1998;95:5843-5844.